Intelligent Bio Solutions Inc. (NASDAQ: INBS)

The QualityStocks Daily Newsletter would like to spotlight Intelligent Bio Solutions Inc. (NASDAQ: INBS).

Intelligent Bio Solutions (NASDAQ: INBS) CEO Harry Simeonidis joined the latest episode of The BioMedWire Podcast to discuss the company's rapid, non-invasive drug screening platform and global expansion strategy. Simeonidis detailed how the company's fingerprint-based technology detects drug use through sweat, enabling faster and more affordable workplace screening. With current deployments in about 20 countries and an FDA application under review, Intelligent Bio Solutions is targeting U.S. market entry in the second half of 2025 and expects to scale through distributor partnerships and targeted marketing.

To view the full article, visit https://ibn.fm/qmoc6

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.

The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers companies and organizations to screen more efficiently. INBS continues to drive adoption in international markets, with customers spanning construction, logistics, healthcare, government, and drug treatment sectors.

INBS’s mission is centered on delivering accessible, transformative solutions that improve lives and operational safety. As the company expands toward a planned U.S. market launch in 2025, it is also strengthening its intellectual property portfolio and localizing solutions for Spanish-speaking regions.

The company is headquartered in New York, New York.

Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions’ flagship offering is the Intelligent Fingerprinting Drug Screening System, a portable, three-part solution that includes a fingerprint collection cartridge, a lateral flow-based DSR-Plus reader, and software for rapid drug screening. Designed to be used on-site, this system eliminates the complexities and hazards of urine and saliva tests, offering a clean, fast, and non-invasive alternative.

The system screens for a broad range of substances including opiates, methamphetamine, cocaine, cannabis, benzodiazepines, and more. Its cost advantage is significant — point-of-care fingerprint tests cost approximately $20, compared to $300 for typical urine or saliva testing. The platform includes over 1,000 DSR-Plus Readers installed across customer sites, supporting a base of more than 450 active customer accounts globally. In clinical studies, the system demonstrated 94.1% accuracy and 100% specificity, providing a credible foundation for future FDA approvals and market expansion.

In addition to drug screening, INBS is developing a proprietary biosensor platform designed to detect specific biomarkers from non-invasive samples such as sweat, saliva, and interstitial fluid. These additional applications remain under development.

Market Opportunity

Intelligent Bio Solutions operates at the intersection of workplace safety, public health, and diagnostic innovation. The company is targeting the drug screening products market, which is projected to reach $14.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.1%, according to Research and Markets.

In the U.S., substance abuse is a $400 billion issue, with more than 70% of individuals using illicit drugs or alcohol currently employed. This presents an urgent need for scalable, workplace-compatible screening technologies. Industries such as transportation, construction, mining, and healthcare are among the highest adopters of employee drug testing protocols, driven by regulatory requirements and safety imperatives.

INBS’s non-invasive solution is well-positioned to capitalize on trends toward less invasive, faster, and more convenient testing methods — potentially displacing legacy systems reliant on urine or saliva testing, which have longer turnaround times and greater administrative burdens.

Leadership Team

Harry Simeonidis, Chief Executive Officer, has over 25 years of experience across the healthcare, pharmaceutical, and life sciences industries. He previously served as General Manager for Surgery, Asia Pacific at GE Healthcare. Prior to that, he was President and CEO of GE Healthcare ANZ, where he led significant market share growth.

Spiro Sakiris, Chief Financial Officer, brings 34 years of expertise in accounting, taxation, IPO preparation, and capital raising. He is highly experienced with IFRS and U.S. GAAP applications in the life sciences sector and is a member of the Institute of Chartered Accountants of Australia & New Zealand.

Intelligent Bio Solutions Inc. (NASDAQ: INBS), closed Tuesday's trading session at $1.93, up 1.5789%, on 1,294,100 volume. The average volume for the last 3 months is 99,343,965 and the stock's 52-week low/high is $0.7505/$19.765.

Recent News

• Intelligent Bio Solutions Inc. (NASDAQ: INBS) - BioMedNewsBreaks - Intelligent Bio Solutions Inc. (NASDAQ: INBS) CEO Highlights Fingerprint Drug Testing on BioMedWire Podcast
• BioMedNewsBreaks - Intelligent Bio Solutions Inc. (NASDAQ: INBS) Expands U.S. Forensic Market Presence Through SMARTOX Partnership
• Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)

The QualityStocks Daily Newsletter would like to spotlight LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF).

LaFleur Minerals' fully permitted Beacon Gold Mill, acquired in 2024 and refurbished by its previous owner, offers a low-cost path to production with an estimated restart budget of C$5-6 million.

The Swanson Gold Project's 2024 mineral resource estimate of 123,400 oz indicated and 64,500 oz inferred, alongside a 5,000-meter drilling program, supports the company's goal of growing the resource toward 1 million ounces.

Consolidation of 15,290 hectares, including acquisitions from Monarch Mining, Abcourt Mines, and Globex Mining, has positioned LaFleur as a formidable exploration company in the Abitibi Gold Belt.

LaFleur's hub-and-spoke development model, centered on its Beacon Mill, supports custom milling opportunities and enhances value from regional partnerships.

A highly experienced leadership team with over 100 years of combined expertise across mining, finance, and capital markets underpins the company's transition from exploration to production.

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is a Canadian exploration and development company advancing the district-scale Swanson Gold Project in Québec’s prolific Abitibi Gold Belt and progressing toward the near-term restart of gold production at its wholly owned Beacon Gold Mill. The company’s strategy centers on consolidating strategic land packages—highlighted by its flagship Swanson Gold Project, a 160 km² district-scale property that includes several prospects rich in gold and critical metals previously held by Monarch Mining, Abcourt Mines, and Globex Mining. The company is leveraging its 100%-owned, fully permitted and recently refurbished Beacon Gold Mill to transition from explorer to near-term gold producer—a key inflection point that typically triggers a market re-rating, further bolstered by current rising gold market prices. By processing material from Swanson and offering custom milling to regional projects, LaFleur aims to generate cash flow with minimal capital outlay, targeting annual gold production of up to 15,000 to 20,000 ounces by early 2026.

LaFleur’s vision is to evolve into an intermediate gold producer by capitalizing on strong market conditions and Québec’s rich mining infrastructure. The location, in the world-class Abitibi Gold Belt, and its infrastructure advantage, positions LaFleur for regional consolidation, strategic partnerships, or acquisition interest. Its mission emphasizes efficient value creation through methodical exploration, low-cost asset advancement, and opportunistic acquisitions—including land and deposits from Monarch Mining, Abcourt Mines, and Globex Mining.

Québec ranks among the world’s top mining jurisdictions, offering access to flow-through capital and regulatory stability. LaFleur’s integrated strategy—combining exploration at Swanson, a permitted mill at Beacon, and potential custom milling agreements—supports a streamlined path to near-term production.

LaFleur Minerals is headquartered in Vancouver, British Columbia.

Projects

LaFleur Minerals’ operations focus on two strategically located assets in the Abitibi Gold Belt: the Swanson Gold Project and the Beacon Gold Mill and Mine. These projects leverage the region’s world-class mining infrastructure and high-grade gold potential to drive the company’s transition to production.

Swanson Gold Project

The Swanson Gold Project spans 16,600 hectares and hosts the Swanson, Bartec, and Jolin gold deposits along a major structural break in the Abitibi Gold Belt. The 2024 Mineral Resource Estimate for the Swanson deposit outlines 123,400 oz of gold in Indicated category (2.1 million tonnes at 1.8 g/t) and 64,500 oz in Inferred category (872,000 tonnes at 2.3 g/t). Located 66 km north of Val-d’Or, the Project is accessible by road and rail and benefits from more than 36,000 meters of historical drilling, along with existing infrastructure including an 80-meter decline portal.

Recent work—including airborne magnetics, soil sampling, and Induced Polarization surveys—has identified multiple high-priority targets and resulted in several high-grade gold assay results, including a grab sample grading 11.71 g/t Au at Jolin, which points to significant upside as the Company prepares to test multiple new zones.

LaFleur has defined over 50 drill targets at Swanson and nearby prospects (Bartec, Jolin, Marimac) and is completing a minimum 5,000-metre diamond drilling beginning in June 2025. LaFleur Minerals has also initiated permitting for a 100,000-tonne surface bulk sample averaging 1.89 g/t Au, which it plans to process at the Beacon Gold Mill as part of a near-term production strategy.

Beacon Gold Mill

LaFleur’s 100%-owned Beacon Gold Mill is a fully refurbished and permitted mill and tailings storage facility capable of processing 750 tonnes per day (tpd), with potential expansion to 1,800 tpd, with access to numerous nearby gold deposits that could be prime sources of ore. Located only 60 km from Swanson, it underwent a $20 million upgrade by Monarch Mining in 2022 and has been under care and maintenance since early 2023. LaFleur is finalizing a C$5-6 million restart plan, ramping up production by late 2025 into early 2026, processing Swanson mineralized material and assessing custom milling opportunities for regional deposits, creating multiple potential revenue streams.

The Beacon Gold Mill is a de-risked, proven asset that benefits from existing infrastructure, including access to roads, power, and skilled labor, and further enhances the overall value proposition of LaFleur by providing a clear path to production and potential revenue-generation.

Market Opportunity

LaFleur Minerals is targeting the gold mining and processing market in Québec’s Abitibi Gold Belt, one of the world’s most productive gold regions. Its fully permitted Beacon Gold Mill, with a 750 tpd capacity and authorization to process 1.8 million tonnes of tailings, is strategically positioned to handle material from LaFleur’s Swanson Gold Project and to offer custom milling for nearby deposits such as Granada Gold. The company projects annual production of over 30,000 ounces of gold once in full production, with potential for significant revenue generation based on prevailing market prices.

Global demand for gold remains robust, driven by geopolitical risk, inflation hedging, and central bank accumulation. The World Gold Council forecasts 3-5% annual demand growth through 2030, with average prices expected between $3,200 and $3,500/oz. Within this environment, Québec’s top-tier mining jurisdiction—ranked fifth globally by the Fraser Institute in 2023—offers streamlined permitting and access to flow-through capital. LaFleur’s low-cost Beacon restart (C$5-6 million) and proximity to more than 100 active and historical mines position the company to fill a growing need for small-to-medium scale custom milling.

At Swanson, LaFleur plans to grow its current 187,900-ounce resource toward 1 million ounces through its 2025 drilling program. This hub-and-spoke strategy, leveraging centralized milling and strong local infrastructure, reduces development risk and strengthens LaFleur’s foothold in one of the most attractive gold belts in the world.

Leadership Team

Kal Malhi, Chairman, is a successful entrepreneur and the Founder of Bullrun Capital Inc., where he has raised over $300 million for early-stage companies across the mining, oil and gas, biomedical, agriculture, and technology sectors. He specializes in advancing academic research into commercial ventures and public listings, with more than two decades of capital markets and leadership experience.

Paul Ténière, M.Sc., P.Geo., Chief Executive Officer, is a seasoned mining executive and Professional Geologist with over 25 years of global experience in the development of precious and base metals, critical minerals, and metallurgical coal projects. Mr. Ténière is an expert in NI 43-101 and S-K 1300 disclosure standards and has held senior roles including President & CEO, SVP Exploration, and Director with several publicly traded mining companies. Mr. Ténière also worked at the Toronto Stock Exchange (TSX) and TSX Venture Exchange as a mining expert and Senior Listings Manager listing dozens of mining companies and ensuring listed issuers met their corporate governance and compliance and disclosure requirements.

Harry Nijjar, Chief Financial Officer and Corporate Secretary, serves as Managing Director at Malaspina Consultants Inc., providing CFO and strategic financial advisory services to companies across multiple industries. He holds a CPA CMA designation from the Chartered Professional Accountants of British Columbia and a Bachelor of Commerce from the University of British Columbia.

Louis Martin, P.Geo., Technical Advisor and Exploration Manager, is a veteran geologist with more than 40 years of exploration experience. He has played key roles in significant gold and base metal discoveries, including the Louvicourt (1989) and West Ansil (2005) deposits—both recognized by the Association de l’Exploration Minière du Québec (AEMQ). He previously served as VP Exploration at Clifton Star Resources, where he led the pre-feasibility study for the 4.5 million-ounce Duparquet Gold Project. He is a registered geologist in Québec and Ontario.

Tara Asfour, Corporate Communications, Investor Relations and Strategy, is an experienced executive consultant with over 12 years of management, investor relations, communications and marketing experience, specialized in capital markets. In her previous positions, Ms. Asfour has led over US$550 million worth of fundraising and strategic development initiatives. Ms. Asfour holds a Master’s degree in Business Management, a Financial Markets Certificate from Yale University, and a Certificate in Alternative Investments from HBS. Previous positions include investor relations executive at Red Pine Exploration, Fancamp Exploration, Communications Director at Dominion Water Reserves (now Prime Drink Group Corp) and advisor to various other publicly listed firms in the resource and technology sectors. Ms. Asfour holds the Institute for Governance (IGOPP) Certification in Governance, Ethics in Business Environment and Corruption Prevention.

Peter Espig, Strategic Advisor and Consultant, has served as Vice-President at Goldman Sachs Japan in both the Principal Finance and Securitization Group and the Asia Special Situations Group, where his team participated in more than $10 billion in structured deals, capital raises, and cross-border transactions. Prior to Goldman Sachs, he was Vice-President at Olympus Capital, a New York-based private equity firm, where he focused on corporate restructurings, investment analysis, and international financing negotiations. He also played a pioneering role in some of the earliest SPAC transactions, totaling over US$1.2 billion, and brings deep experience in disciplined capital deployment and turnaround execution. Since 2013, Mr. Espig has served as President and CEO of Nicola Mining Inc. and is a board member of ESGold Corp and First Lithium Minerals. Mr. Espig holds a Bachelor of Arts from the University of British Columbia and an MBA from Columbia Business School, where he was a Chazen International Scholar. He has served on various public boards and was recognized among Industry Era’s “Top 10 Admired Leaders” in 2023.

Jean Lafleur, Senior Technical Advisor, is a Professional Geologist (Québec) with 45 years of experience in Canada and internationally including USA, Mexico, Latin America, Ireland, Spain and Africa. Earlier in his career he worked with Newmont, Falconbridge, Dome Mines, and Placer Dome and has been a C-suite executive for a number of junior exploration companies. Jean has remained active as a technical, management, and financing consultant with junior explorers since the early 2000’s through his own geological consultancy firm and throughout his career has led a number of teams in the discovery of precious and base metals, nickel, PGE’s, uranium, and iron deposits. Jean’s expertise includes mining company and project evaluations, audits, technical reporting, exploration program planning and execution, and research and development with a strong focus on Québec. Jean currently acts as a Senior Consultant, North America for Appian Capital Advisory LLP, a mining-focused private equity firm based in London, UK where through his extensive professional network he sources and presents potential mining transactions in North America to the Appian team for investment opportunities.

LaFleur Minerals Inc. (OTCQB: LFLRF), closed Tuesday's trading session at $0.225, off by 5.1033%, on 2,544 volume. The average volume for the last 3 months is 423,594 and the stock's 52-week low/high is $1.1/$6.01.

Recent News

• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Is 'One to Watch'
• MiningNewsBreaks - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Advances Swanson Drilling and Beacon Mill Restart with Exploration Success and Strategic Appointment
• RockBreaks - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Initiates Bulk Sample Permitting at Swanson Gold Project Ahead of Beacon Mill Restart 

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Behçet's disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and Japan.

Even with treatment, symptoms can continue occurring for many patients and significantly affect their quality of life and productivity.

Soligenix has initiated a clinical trial to evaluate the safety, tolerability and preliminary efficacy of SGX945 in patients suffering from oral ulcers.

Behçet's disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies, notably SGX945 (dusquetide), aiming to address the unmet need in this challenging disease landscape ( https://ibn.fm/KByRu ).

A recently published analysis that appeared in the Journal of American Academy of Dermatology has concluded that the general percentage of adults in the U.S. diagnosed with psoriasis remains unchanged at 3% over the past 10 years. However, the investigators mention several points of concern that aren't reflected in this general summary.  For starters, they point out that the population in America has expanded. Consequently, a stable overall percentage of individuals diagnosed with psoriasis shouldn't be taken to mean that the caseload has decreased. For example, at the current U.S. population, 3% translates into approximately 8 million individuals, which is a large number. There is need to conduct comprehensive community engagement in underserved areas while also improving dermatological care access in those areas. Further research should also be more intentional about capturing data on all ethnic groups since the existing studies largely had Whites as study subjects.  The estimates of how many people within the U.S. suffer from psoriasis are concerning. As more is done to improve access to diagnostic services, it is also urgent to develop effective treatments against this condition. The R&D efforts being undertaken by firms like Soligenix Inc. (NASDAQ: SNGX) are a step in the right direction. 

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $1.8, even for the day, on 1,337 volume. The average volume for the last 3 months is 73,590 and the stock's 52-week low/high is $2.55/$6.118.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Study Finds the Overall Prevalence of Psoriasis in the US Unchanged
• Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet's Disease
• InvestorNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025-2026

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Electric vehicles sales in Europe are rebounding from several months of slowed adoption and outright boycotts of some EV brands. Although Europe is the second largest electric vehicle market, 2024 saw a growing number of European buyers refrain from EV purchases due to costs, range anxiety, and brand controversies. Recent data now shows that electric vehicle sales in Europe are seeing a resurgence, but EV adoption remains uneven across the continent. New vehicle registrations by Volkswagen and BMW increased by 4.5% and 2.3% respectively in Q1 2025, indicating increased interest in electric cars among European drivers. The European Automobile Manufacturers' Association notes that buyers across the EU, Iceland, Switzerland, and Norway registered more than 2.2 million new electric cars between January and April 2025. This includes battery electric vehicles (BEVs), plug-in hybrid electric vehicles (PHEVs), and hybrid electric vehicles (HEVs). Fortunately, both markets and the broader EU saw an improvement in their BEV electric vehicle sales in Q1 2025 primarily due to a European EV mandate that forced companies to lower their fleet carbon dioxide emissions from 2021 levels by 15%. This resulted in a surge of corporate vehicle purchases that pushed EV sales across the EU and in Germany especially. German carmakers like Stellantis and Volkswagen have also spent the past several months launching new electric vehicle models and rolling out appealing leasing options to encourage firms to speed up efforts to electrify their fleets. If this revived buyer interest is sustained across all markets, not just in Europe, many firms like Massimo Group (NASDAQ: MAMO) could see a marked uptick in their sales over the coming months. 

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Tuesday's trading session at $2.06, off by 1.9048%, on 43,891 volume. The average volume for the last 3 months is 493,237 and the stock's 52-week low/high is $1.23/$6.65.

Recent News

• Massimo Group (NASDAQ: MAMO) - Electric Vehicle Sales are Rebounding in Europe
• InvestorNewsBreaks – Driving the Future of Powersports: Massimo Group’s (NASDAQ: MAMO) Bold Strategy for Market Growth
• Ongoing Rare Earths Shortages Force Maruti Suzuki to Cut EV Production

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Experts say that glitches in renewable energy supply don't always indicate failure in clean energy systems. When the Iberian Peninsula experienced a blackout that lasted more than 10 hours, some commentators questioned whether renewable energy was to blame. The region gets more than 60% of its electricity from green sources, so when parts of mainland Spain, Portugal, and even areas of France went dark, some assumed that solar or wind systems were the cause. However, Spanish grid operator Red Eléctrica (REE) and Spain's energy minister rejected those claims, stating that renewables were not the cause of the disruption. A task force has been formed to investigate the real reasons behind the blackout. According to REE, a number of factors contributed to the outage. These included limited investment in modernizing the power grid, malfunctions at traditional power stations, and unforeseen shutdowns of solar power installations. As the world moves toward decarbonization, setbacks in renewable energy should be seen as stepping stones, not stop signs. Embracing these challenges will allow nations to refine systems, build resilience, and develop sustainable infrastructure capable of supporting future energy needs without sacrificing stability, reliability, or long-term climate goals. Those growing pains are comparable to what happened in the early days of electric vehicles. Current models from entities like Mullen Automotive Inc. (NASDAQ: MULN) were built on the lessons learned from earlier efforts, and the technology is now far more reliable than it was a decade ago.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $1.65, off by 23.6111%, on 10,464 volume. The average volume for the last 3 months is 120,385 and the stock's 52-week low/high is $1.45/$3.48.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - Why Renewable Energy Glitches Aren't Necessarily Signals of Failure
• Google Teams Up with CIP on Wind Energy Project in Taiwan
• Japanese Firm Makes Tiny $7k EV Outselling Toyota EV Models

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam to integrate AccurECG(TM), AccurKardia's FDA-cleared ECG analysis software

Collaboration enhances HeartBeam's commercial offering with automated arrhythmia insights

Combined platform aims to improve cardiac care access and speed time to diagnosis

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with AccurKardia , a leader in automated ECG diagnostics, to integrate its FDA-cleared AccurECG(TM) software into HeartBeam's cable-free, credit card-sized 3D ECG device. The partnership unites two innovators in ambulatory cardiac monitoring to create a more scalable, accessible solution for arrhythmia detection and management.

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (SAM), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (MI), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (MCOT) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $1.55, off by 9.3567%, on 4,478 volume. The average volume for the last 3 months is 1,476,561 and the stock's 52-week low/high is $0.99/$2.27.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG
• HeartBeam Inc. (NASDAQ: BEAT) Is 'One to Watch'

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

Women make up roughly 28% of on-course golfers in the United States, a historic high.

The global golf equipment market is booming, generating an estimated $25.5 billion in 2024 and projected to grow at nearly 6% annually.

Newton Golf's lighter shaft is engineered to weigh less than previous versions while maintaining precision, stability and distance.

A surge in women's golf participation is reshaping the industry, drawing fresh energy and opportunity to equipment manufacturers. Newton Golf Company (NASDAQ: NWTG) recently released the perfect piece of equipment for this dynamic market — a lighter shaft option, designed to deliver premium performance for golfers of all levels, from weekend enthusiasts to tour professionals, who are widely adopting the new shaft in competition.

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Tuesday's trading session at $1.55, off by 1.2739%, on 13,270 volume. The average volume for the last 3 months is 266,450 and the stock's 52-week low/high is $0.0139/$1.65.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - Newton Golf Company Inc. (NASDAQ: NWTG) Unveils Lighter Shaft amid Women's Golf Boom
• InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Names Jeff Clayborne as CFO to Drive Next Phase of Growth
• NetworkNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) CEO Greg Campbell to Appear at IBN TableTalk Roadshow 

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

ESGold (CSE: ESAU) (OTCQB: ESAUF) announced a non-brokered private placement of units priced at $0.73 each, targeting gross proceeds of up to $3.285 million. Each unit comprises one common share and one share purchase warrant, exercisable at $0.91 for 18 months. The initial closing is scheduled for June 20, 2025, with additional tranches possible. Proceeds will support mill circuit construction, final mobilization at the Montauban Gold-Silver Project, and general working capital. The placement remains subject to Canadian Securities Exchange approval.

To view the full press release, visit https://ibn.fm/eoftS

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

ESGold Corp. (OTCQB: ESAUF), closed Tuesday's trading session at $0.6691, off by 1.3476%, on 276,168 volume. The average volume for the last 3 months is 329,640 and the stock's 52-week low/high is $0.33/$1.64.

Recent News

• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) - RockBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Launches $3.3 Million Private Placement to Advance Montauban Project
• InvestorNewsBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) CEO Talks Near-Term Production and Clean Mining Focus on Exploring Mining Podcast 
• MiningNewsBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Advances Toward First Production at Montauban Project

ONAR Holding Corp. (OTCQB: ONAR)

The QualityStocks Daily Newsletter would like to spotlight ONAR Holding Corp. (OTCQB: ONAR).

ONAR Holding Corp. (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

• Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
• Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
• CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
• ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

ONAR Holding Corp. (OTCQB: ONAR), closed Tuesday's trading session at $0.0649, up 27.2549%, on 550,117 volume. The average volume for the last 3 months is 600,870 and the stock's 52-week low/high is $0.0143/$0.1005.

Recent News

• ONAR Holding Corp. (OTCQB: ONAR) - ONAR Holding Corp. (ONAR) Takes the Lead in AI-Driven Marketing as CEO Shares Vision
• From Basement Studio Success to Marketing Visionary: CEO of ONAR Holding Corp. (ONAR)
• InvestorNewsBreaks - ONAR Holding Corp. (OTCQB: ONAR) Appoints Howard Palefsky to Board, Expands Governance Leadership 

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Tuesday's trading session at $7.75, up 2.2427%, on 714 volume. The average volume for the last 3 months is 67,074 and the stock's 52-week low/high is $3.7223/$11.78.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology
• Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.829, up 2.2195%, on 241,755 volume. The average volume for the last 3 months is 3,798,647 and the stock's 52-week low/high is $1.62/$169182000.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit
• Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis
• Experts Say New Test for Brain Tumors is a Game-Changer

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM)

The QualityStocks Daily Newsletter would like to spotlight Silvercorp Metals Inc. (TSX.V: SVM) (NYSE American: SVM).

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

• Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
• GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
• El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully-funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
• Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
• Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
• BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
• Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman & CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

Silvercorp Metals Inc. (NYSE American: SVM), closed Tuesday's trading session at $4.5, up 2.0408%, on 4,518 volume. The average volume for the last 3 months is 3,995,532 and the stock's 52-week low/high is $0.7715/$200.

Recent News

• Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) - InvestorNewsBreaks - Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Files Updated Resource Estimate for Condor Gold Project in Ecuador 
• MiningNewsBreaks - Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Files Fiscal 2025 Annual Report With SEC
• Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) Is 'One to Watch'